Session » Rheumatoid Arthritis - Animal Models Poster

Date: Tuesday, November 10, 2015

Time: 9:00AM-11:00AM

Meeting: 2015 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2555

14-3-3η As a Novel RA Drug Target: Anti-14-3-3η Monoclonal Antibody Delays the Onset and Mitigates the Severity of Arthritis in CIA Mice

9:00AM-11:00AM: Abstract Number: 2577

Ablation of Fc Gamma Receptors Leads to a Decreased Bone Erosion in Experimental Arthritis Not By Altering Osteoclast Numbers within the Inflamed Joint but By Inhibiting Osteoclast Activation

9:00AM-11:00AM: Abstract Number: 2565

ACPA Specific IVIG Attenuate Collagen Induced Arthritis in Mice

9:00AM-11:00AM: Abstract Number: 2580

Age-Related Differences in Collagen-Induced Arthritis: Clinical, Imaging and Biological Characteristics in Juvenile Compared to Adult Animals

9:00AM-11:00AM: Abstract Number: 2552

Alterations in the Colonic Microbiome Precede the Development of Murine Inflammatory Arthritis

9:00AM-11:00AM: Abstract Number: 2571

Anti-IL-6 Receptor Antibody Prevents Loss of Bone Strength in a Mouse Model of Collagen-Induced Arthritis

9:00AM-11:00AM: Abstract Number: 2551

Antibodies to Malondialdehyde-Acetaldhyde Adducts Are Increased in the Serum of Mice Following Infection with P. Gingivalis and/or Injection of Citrullinated Mouse Type II Collagen: a Model of Human Disease Response

9:00AM-11:00AM: Abstract Number: 2578

Cardiovascular Effects of Etanercept in an Animal Model of Rheumatoid Arthritis: Mechanisms Involved

9:00AM-11:00AM: Abstract Number: 2549

Characterizing the RPTPσ Mediated Proteoglycan Switch As a Target for Rheumatoid Arthritis Therapy

9:00AM-11:00AM: Abstract Number: 2557

Comparable Therapeutic Potential of Umbilical Cord Mesenchymal Stem Cells in Collagen Induced Arthritis with Anti-Tumor Necrosis Factor or Anti-CD20

9:00AM-11:00AM: Abstract Number: 2570

Comparative Analysis of Collagen-Antibody Induced Arthritis and the Arthritis Inhibitory Potential of Specific ACPA in Two Mouse Subspecies Genetically Separated about One Million Years Ago

9:00AM-11:00AM: Abstract Number: 2573

Confirmatory Analysis of Methylome Signatures in Rheumatoid Arthritis Using an Independent Dataset

9:00AM-11:00AM: Abstract Number: 2579

Effect of Tacrolimus on Endoplasmic Reticulum Stress-Mediated Osteoclastogenesis in a Collagen-Induced Arthritis Mouse Model

9:00AM-11:00AM: Abstract Number: 2556

Functional Genetics of PTPN2 in Rheumatoid Arthritis: Haploinsufficiency of PTPN2 Promotes Severity of CD4+ T-Cell Mediated Autoimmune Arthritis

9:00AM-11:00AM: Abstract Number: 2563

Immune Regulation By Migrating Mesenchymal Stem Cells Ameliorate Inflammatory Arthritis in Mice

9:00AM-11:00AM: Abstract Number: 2583

Important Role of CD11c+ Dendritic Cells in Inflammatory Arthritis

9:00AM-11:00AM: Abstract Number: 2582

Increased Morbidity and Mortality in Female Versus Male Tumor Necrosis Factor-Transgenic Mice

9:00AM-11:00AM: Abstract Number: 2554

Inhibition of IL6 Receptor Improves Arthritis and Atherosclerosis in a Mouse Model of Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2553

Involvement of M2 Macrophages in the Pathogenesis of Arthritis in a Mouse Model

9:00AM-11:00AM: Abstract Number: 2548

M-CSF-R Is a Critical Determinant for the Differentiation of Classical to Non-Classical Monocytes

9:00AM-11:00AM: Abstract Number: 2550

Metabolomic Profiling of Joints in Murine Models of Inflammatory Arthritis

9:00AM-11:00AM: Abstract Number: 2547

NIP-565, a Novel JAK1-Selective Inhibitor, for the Treatment of Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2566

Novel Therapeutic Compound Tuftsin-Phosphorylcholine Attenuate Collagen Induced Arthritis

9:00AM-11:00AM: Abstract Number: 2564

Nuclear Receptor 4A2 Is Selectively Upregulated in the Human TNF-Alpha Transgenic Model of Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2559

PRO-Resolving Mediators Issued from Apoptotic CELL Efferocytosis (SUPERMAPO) Modulate Antigen Presenting CELL Properties Toward a Tolerogenic Profile: Efficacy in the Treatment of Collagen- Induced Arthritis

9:00AM-11:00AM: Abstract Number: 2572

Protective and Therapeutic Effects of Growth Hormone on Collagen-Induced Arthritis

9:00AM-11:00AM: Abstract Number: 2569

Regulation of SIRT1 Maybe a Perfect Strategy in Treatment of Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2574

Rheumatoid Arthritis Leads to Altered Gene Expression in the Brain and Behavioral Changes in Mice

9:00AM-11:00AM: Abstract Number: 2567

SPACIA1/SAAL1-Deficient Mice Show Reduced Disease Progression in Collagen-Induced Arthritis

9:00AM-11:00AM: Abstract Number: 2546

Targeting Synovial Fibroblasts By the Intra-Articular Delivery of microRNA-140-3p and -5p Ameliorates Experimental Autoimmune Arthritis

9:00AM-11:00AM: Abstract Number: 2561

TAS5315, a Novel Bruton’s Tyrosine Kinase (BTK) Inhibitor, Demonstrates Potent Efficacy in an Animal Model of Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2575

The Effect of mPGES-1 Deletion on Platelet Function in Mice

9:00AM-11:00AM: Abstract Number: 2562

The Inhibition of Wnt/Beta-Catenin Signaling Pathway Via Paricalcitol and Pyrvinium Ameliorates Experimental Arthritis

9:00AM-11:00AM: Abstract Number: 2560

The Mer Tyrosine Kinase Receptor Plays a Protective Role in Joint Inflammation By Mediating Efferocytosis

9:00AM-11:00AM: Abstract Number: 2568

The Osteoimmunological Mechanistic Basis of Low-Dose Radiotherapy in TNF Driven Arthritis

9:00AM-11:00AM: Abstract Number: 2558

The Role of Leukocyte Associated Immunoglobulin-like Receptor-1 (LAIR-1) in Collagen-Induced Arthritis

9:00AM-11:00AM: Abstract Number: 2581

TNF-Alpha Receptor II Signaling Plays an Important Role in Maintaining the Expression of Forkhead Box P3 in Murine Regulatory T Cells

9:00AM-11:00AM: Abstract Number: 2576

Treatment of Inflammatory Arthritis with a Hybrid Compound, LLP2A-Ale, Can Prevent Joint Destruction

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].